The DOI matches its Crossref record; 164 of the 164 references it cites were found in a registry or an index.
Research progress of therapeutic effects and drug resistance of immunotherapy based on PD-1/PD-L1 blockade
Abstract
The binding of programmed death-1 (PD-1) on the surface of T cells and PD-1 ligand 1 (PD-L1) on tumor cells can prevent the immune-killing effect of T cells on tumor cells and promote the immune escape of tumor cells. Therefore, immune checkpoint blockade targeting PD-1/PD-L1 is a reliable tumor therapy with remarkable efficacy. However, the main challenges of this therapy are low response rate and acquired resistance, so that the outcomes of this therapy are usually unsatisfactory. This review begins with the description of biological structure of the PD-1/PD-L1 immune checkpoint and its role in a variety of cells. Subsequently, the therapeutic effects of immune checkpoint blockers (PD-1 / PD-L1 inhibitors) in various tumors were introduced and analyzed, and the reasons affecting the function of PD-1/PD-L1 were systematically analyzed. Then, we focused on analyzing, sorting out and introducing the possible underlying mechanisms of primary and acquired resistance to PD-1/PD-L1 blockade including abnormal expression of PD-1/PD-L1 and some factors, immune-related pathways, tumor immune microenvironment, and T cell dysfunction and others. Finally, promising therapeutic strategies to sensitize the resistant patients with PD-1/PD-L1 blockade treatment were described. This review is aimed at providing guidance for the treatment of various tumors, and highlighting the drug resistance mechanisms to offer directions for future tumor treatment and improvement of patient prognosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Microenvironmental regulation of tumor progression and metastasis
Quail, D. F., & Joyce, J. A. (2013) · Nature Medicine · doi:10.1038/nm.3394 · Cited by 7,994
The future of immune checkpoint therapy
Sharma, P., & Allison, J. P. (2015) · Science · doi:10.1126/science.aaa8172 · Cited by 4,878
Tumour-associated macrophages as treatment targets in oncology
Mantovani, A., Marchesi, F., Malesci, A., Laghi, L., & Allavena, P. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.217 · Cited by 4,033
A framework for advancing our understanding of cancer-associated fibroblasts
Sahai, E., Astsaturov, I., Cukierman, E., DeNardo, D. G., Egeblad, M., Evans, R. M., Fearon, D., Greten, F. R., Hingorani, S. R., Hunter, T., et al. (2020) · Nature Reviews Cancer · doi:10.1038/s41568-019-0238-1 · Cited by 3,863
Approaches to treat immune hot, altered and cold tumours with combination immunotherapies
Galon, J., & Bruni, D. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0007-y · Cited by 3,409
The Tumor Microenvironment Innately Modulates Cancer Progression
Hinshaw, D. C., & Shevde, L. A. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-3962 · Cited by 3,270
Ishida, Y., Agata, Y., Shibahara, K., & Honjo, T. (1992) · The EMBO Journal · doi:10.1002/j.1460-2075.1992.tb05481.x · Cited by 3,256
FOXP3+ regulatory T cells in the human immune system
Sakaguchi, S., Miyara, M., Costantino, C. M., & Hafler, D. A. (2010) · Nature Reviews Immunology · doi:10.1038/nri2785 · Cited by 2,439
Zou, W., Wolchok, J. D., & Chen, L. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aad7118 · Cited by 2,400
Greenwald, R. J., Freeman, G. J., & Sharpe, A. H. (2005) · Annual Review of Immunology · doi:10.1146/annurev.immunol.23.021704.115611 · Cited by 2,318
PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity
Gordon, S. R., Maute, R. L., Dulken, B. W., Hutter, G., George, B. M., McCracken, M. N., Gupta, R., Tsai, J. M., Sinha, R., Corey, D., et al. (2017) · Nature · doi:10.1038/nature22396 · Cited by 2,247
Top 10 Challenges in Cancer Immunotherapy
Hegde, P. S., & Chen, D. S. (2020) · Immunity · doi:10.1016/j.immuni.2019.12.011 · Cited by 2,238
Regulation and Function of the PD-L1 Checkpoint
Sun, C., Mezzadra, R., & Schumacher, T. N. (2018) · Immunity · doi:10.1016/j.immuni.2018.03.014 · Cited by 2,193
PD-L1 regulates the development, maintenance, and function of induced regulatory T cells
Francisco, L. M., Salinas, V. H., Brown, K. E., Vanguri, V. K., Freeman, G. J., Kuchroo, V. K., & Sharpe, A. H. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20090847 · Cited by 2,079
The diverse functions of the PD1 inhibitory pathway
Sharpe, A. H., & Pauken, K. E. (2018) · Nature Reviews Immunology · doi:10.1038/nri.2017.108 · Cited by 1,971
Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression
Garcia-Diaz, A., Shin, D. S., Moreno, B. H., Saco, J., Escuin-Ordinas, H., Rodriguez, G. A., Zaretsky, J. M., Sun, L., Hugo, W., Wang, X., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.04.031 · Cited by 1,942
Macrophages and metabolism in the tumor microenvironment
Vitale, I., Manic, G., Coussens, L. M., Kroemer, G., & Galluzzi, L. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.06.001 · Cited by 1,837
Cancer immunoediting and resistance to T cell-based immunotherapy
O’Donnell, J. S., Teng, M. W. L., & Smyth, M. J. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0142-8 · Cited by 1,759
T cell costimulatory receptor CD28 is a primary target for PD-1–mediated inhibition
Hui, E., Cheung, J., Zhu, J., Su, X., Taylor, M. J., Wallweber, H. A., Sasmal, D. K., Huang, J., Kim, J. M., Mellman, I., et al. (2017) · Science · doi:10.1126/science.aaf1292 · Cited by 1,689
CD8+ cytotoxic T lymphocytes in cancer immunotherapy: A review
Farhood, B., Najafi, M., & Mortezaee, K. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.27782 · Cited by 1,658
Koyama, S., Akbay, E. A., Li, Y. Y., Herter-Sprie, G. S., Buczkowski, K. A., Richards, W. G., Gandhi, L., Redig, A. J., Rodig, S. J., Asahina, H., et al. (2016) · Nature Communications · doi:10.1038/ncomms10501 · Cited by 1,580
Loss of PTEN Promotes Resistance to T Cell–Mediated Immunotherapy
Peng, W., Chen, J. Q., Liu, C., Malu, S., Creasy, C., Tetzlaff, M. T., Xu, C., McKenzie, J. A., Zhang, C., Liang, X., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0283 · Cited by 1,539
Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies
Naidoo, J., Page, D. B., Li, B. T., Connell, L. C., Schindler, K., Lacouture, M. E., Postow, M. A., & Wolchok, J. D. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv383 · Cited by 1,470
Combination strategies with PD-1/PD-L1 blockade: current advances and future directions
Yi, M., Zheng, X., Niu, M., Zhu, S., Ge, H., & Wu, K. (2022) · Molecular Cancer · doi:10.1186/s12943-021-01489-2 · Cited by 1,445
Haslam, A., & Prasad, V. (2019) · JAMA Network Open · doi:10.1001/jamanetworkopen.2019.2535 · Cited by 1,413
MYC regulates the antitumor immune response through CD47 and PD-L1
Casey, S. C., Tong, L., Li, Y., Do, R., Walz, S., Fitzgerald, K. N., Gouw, A. M., Baylot, V., Gütgemann, I., Eilers, M., et al. (2016) · Science · doi:10.1126/science.aac9935 · Cited by 1,403
Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway
Boussiotis, V. A. (2016) · New England Journal of Medicine · doi:10.1056/nejmra1514296 · Cited by 1,339
Distinct cellular mechanisms underlie anti-CTLA-4 and anti-PD-1 checkpoint blockade
Wei, S. C., Levine, J. H., Cogdill, A. P., Zhao, Y., Anang, N.-A. A. S., Andrews, M. C., Sharma, P., Wang, J., Wargo, J. A., Pe’er, D., et al. (2017) · Cell · doi:10.1016/j.cell.2017.07.024 · Cited by 1,302
Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting
Matsushita, H., Vesely, M. D., Koboldt, D. C., Rickert, C. G., Uppaluri, R., Magrini, V. J., Arthur, C. D., White, J. M., Chen, Y.-S., Shea, L. K., et al. (2012) · Nature · doi:10.1038/nature10755 · Cited by 1,288
Self-citationThe ‘Shp'ing news: SH2 domain-containing tyrosine phosphatases in cell signaling
Neel, B. G., Gu, H., & Pao, L. (2003) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(03)00091-4 · Cited by 1,249
Chemnitz, J. M., Parry, R. V., Nichols, K. E., June, C. H., & Riley, J. L. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.2.945 · Cited by 1,246
Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy
Peng, D., Kryczek, I., Nagarsheth, N., Zhao, L., Wei, S., Wang, W., Sun, Y., Zhao, E., Vatan, L., Szeliga, W., et al. (2015) · Nature · doi:10.1038/nature15520 · Cited by 1,201
Self-citationOvercoming T cell exhaustion in infection and cancer
Pauken, K. E., & Wherry, E. J. (2015) · Trends in Immunology · doi:10.1016/j.it.2015.02.008 · Cited by 1,171
Yokosuka, T., Takamatsu, M., Kobayashi-Imanishi, W., Hashimoto-Tane, A., Azuma, M., & Saito, T. (2012) · Journal of Experimental Medicine · doi:10.1084/jem.20112741 · Cited by 1,161
ZAP-70: A 70 kd protein-tyrosine kinase that associates with the TCR ζ chain
Chan, A. C., Iwashima, M., Turck, C. W., & Weiss, A. (1992) · Cell · doi:10.1016/0092-8674(92)90598-7 · Cited by 1,041
Resistance to checkpoint blockade therapy through inactivation of antigen presentation
Sade-Feldman, M., Jiao, Y. J., Chen, J. H., Rooney, M. S., Barzily-Rokni, M., Eliane, J.-P., Bjorgaard, S. L., Hammond, M. R., Vitzthum, H., Blackmon, S. M., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01062-w · Cited by 1,005
Neoadjuvant checkpoint blockade for cancer immunotherapy
Topalian, S. L., Taube, J. M., & Pardoll, D. M. (2020) · Science · doi:10.1126/science.aax0182 · Cited by 1,001
Combination of CTLA-4 and PD-1 blockers for treatment of cancer
Rotte, A. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1259-z · Cited by 970
Davis, A. A., & Patel, V. G. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0768-9 · Cited by 960
Liu, S. V., Reck, M., Mansfield, A. S., Mok, T., Scherpereel, A., Reinmuth, N., Garassino, M. C., De Castro Carpeno, J., Califano, R., Nishio, M., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.01055 · Cited by 862
Deubiquitination and Stabilization of PD-L1 by CSN5
Lim, S.-O., Li, C.-W., Xia, W., Cha, J.-H., Chan, L.-C., Wu, Y., Chang, S.-S., Lin, W.-C., Hsu, J.-M., Hsu, Y.-H., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.10.010 · Cited by 793
Sharma, P., Callahan, M. K., Bono, P., Kim, J., Spiliopoulou, P., Calvo, E., Pillai, R. N., Ott, P. A., de Braud, F., Morse, M., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30496-x · Cited by 678
Immunotherapy in Non–Small Cell Lung Cancer: Facts and Hopes
Doroshow, D. B., Sanmamed, M. F., Hastings, K., Politi, K., Rimm, D. L., Chen, L., Melero, I., Schalper, K. A., & Herbst, R. S. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1538 · Cited by 667
Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure)
Kim, J. M., & Chen, D. S. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw217 · Cited by 648
PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations
Jiang, Y., Chen, M., Nie, H., & Yuan, Y. (2019) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2019.1571892 · Cited by 640
The PD1:PD-L1/2 Pathway from Discovery to Clinical Implementation
Bardhan, K., Anagnostou, T., & Boussiotis, V. A. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00550 · Cited by 606
Qin, S., Ren, Z., Meng, Z., Chen, Z., Chai, X., Xiong, J., Bai, Y., Yang, L., Zhu, H., Fang, W., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30011-5 · Cited by 602
Self-citationNon-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance
Hugo, W., Shi, H., Sun, L., Piva, M., Song, C., Kong, X., Moriceau, G., Hong, A., Dahlman, K. B., Johnson, D. B., et al. (2015) · Cell · doi:10.1016/j.cell.2015.07.061 · Cited by 600
Liu, J., Hamrouni, A., Wolowiec, D., Coiteux, V., Kuliczkowski, K., Hetuin, D., Saudemont, A., & Quesnel, B. (2007) · Blood · doi:10.1182/blood-2006-10-051482 · Cited by 580
Restifo, N. P., Marincola, F. M., Kawakami, Y., Taubenberger, J., Yannelli, J. R., & Rosenberg, S. A. (1996) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/88.2.100 · Cited by 533
Structure of the Complex of Human Programmed Death 1, PD-1, and Its Ligand PD-L1
Zak, K. M., Kitel, R., Przetocka, S., Golik, P., Guzik, K., Musielak, B., Dömling, A., Dubin, G., & Holak, T. A. (2015) · Structure · doi:10.1016/j.str.2015.09.010 · Cited by 531
Patsoukis, N., Brown, J., Petkova, V., Liu, F., Li, L., & Boussiotis, V. A. (2012) · Science Signaling · doi:10.1126/scisignal.2002796 · Cited by 529
Roles of PD-1/PD-L1 Pathway: Signaling, Cancer, and Beyond
Ai, L., Xu, A., & Xu, J. (2020) · Advances in Experimental Medicine and Biology · doi:10.1007/978-981-15-3266-5_3 · Cited by 526
Roles of regulatory T cells in cancer immunity
Takeuchi, Y., & Nishikawa, H. (2016) · International Immunology · doi:10.1093/intimm/dxw025 · Cited by 523
Tekguc, M., Wing, J. B., Osaki, M., Long, J., & Sakaguchi, S. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2023739118 · Cited by 490
George, S., Miao, D., Demetri, G. D., Adeegbe, D., Rodig, S. J., Shukla, S., Lipschitz, M., Amin-Mansour, A., Raut, C. P., Carter, S. L., et al. (2017) · Immunity · doi:10.1016/j.immuni.2017.02.001 · Cited by 483
Mechanisms regulating PD-L1 expression on tumor and immune cells
Chen, S., Crabill, G. A., Pritchard, T. S., McMiller, T. L., Wei, P., Pardoll, D. M., Pan, F., & Topalian, S. L. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0770-2 · Cited by 459
Ota, K., Azuma, K., Kawahara, A., Hattori, S., Iwama, E., Tanizaki, J., Harada, T., Matsumoto, K., Takayama, K., Takamori, S., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0016 · Cited by 435
Tumor Immune Microenvironment and Immunosuppressive Therapy in Hepatocellular Carcinoma: A Review
Oura, K., Morishita, A., Tani, J., & Masaki, T. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115801 · Cited by 426
PD-L1 Distribution and Perspective for Cancer Immunotherapy—Blockade, Knockdown, or Inhibition
Wu, Y., Chen, W., Xu, Z. P., & Gu, W. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02022 · Cited by 419
Arce Vargas, F., Furness, A. J. S., Solomon, I., Joshi, K., Mekkaoui, L., Lesko, M. H., Miranda Rota, E., Dahan, R., Georgiou, A., Sledzinska, A., et al. (2017) · Immunity · doi:10.1016/j.immuni.2017.03.013 · Cited by 418
Self-citationStructural and Functional Analysis of the Costimulatory Receptor Programmed Death-1
Zhang, X., Schwartz, J.-C. D., Guo, X., Bhatia, S., Cao, E., Chen, L., Zhang, Z.-Y., Edidin, M. A., Nathenson, S. G., & Almo, S. C. (2004) · Immunity · doi:10.1016/s1074-7613(04)00051-2 · Cited by 410
Cheng, Y., Li, H., Deng, Y., Tai, Y., Zeng, K., Zhang, Y., Liu, W., Zhang, Q., & Yang, Y. (2018) · Cell Death & Disease · doi:10.1038/s41419-018-0458-4 · Cited by 399
Huinen, Z. R., Huijbers, E. J. M., van Beijnum, J. R., Nowak-Sliwinska, P., & Griffioen, A. W. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00496-y · Cited by 395
Zhang, N., Zeng, Y., Du, W., Zhu, J., Shen, D., Liu, Z., & Huang, J.-A. (2016) · International Journal of Oncology · doi:10.3892/ijo.2016.3632 · Cited by 362
Mimura, K., Teh, J. L., Okayama, H., Shiraishi, K., Kua, L., Koh, V., Smoot, D. T., Ashktorab, H., Oike, T., Suzuki, Y., et al. (2018) · Cancer Science · doi:10.1111/cas.13424 · Cited by 329
Wang, X., Yang, L., Huang, F., Zhang, Q., Liu, S., Ma, L., & You, Z. (2017) · Immunology Letters · doi:10.1016/j.imlet.2017.02.006 · Cited by 324
Structure and Interactions of the Human Programmed Cell Death 1 Receptor
Cheng, X., Veverka, V., Radhakrishnan, A., Waters, L. C., Muskett, F. W., Morgan, S. H., Huo, J., Yu, C., Evans, E. J., Leslie, A. J., et al. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.448126 · Cited by 323
Zhang, X., Zeng, Y., Qu, Q., Zhu, J., Liu, Z., Ning, W., Zeng, H., Zhang, N., Du, W., Chen, C., et al. (2017) · International Journal of Clinical Oncology · doi:10.1007/s10147-017-1161-7 · Cited by 316
Alternative p38 activation pathway mediated by T cell receptor-proximal tyrosine kinases
Salvador, J. M., Mittelstadt, P. R., Guszczynski, T., Copeland, T. D., Yamaguchi, H., Appella, E., Fornace, A. J., & Ashwell, J. D. (2005) · Nature Immunology · doi:10.1038/ni1177 · Cited by 306
Temporally Distinct PD-L1 Expression by Tumor and Host Cells Contributes to Immune Escape
Noguchi, T., Ward, J. P., Gubin, M. M., Arthur, C. D., Lee, S. H., Hundal, J., Selby, M. J., Graziano, R. F., Mardis, E. R., Korman, A. J., et al. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0391 · Cited by 302
Reversing T-cell Exhaustion in Cancer: Lessons Learned from PD-1/PD-L1 Immune Checkpoint Blockade
Budimir, N., Thomas, G. D., Dolina, J. S., & Salek-Ardakani, S. (2022) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-21-0515 · Cited by 298
Kluger, H. M., Tawbi, H. A., Ascierto, M. L., Bowden, M., Callahan, M. K., Cha, E., Chen, H. X., Drake, C. G., Feltquate, D. M., Ferris, R. L., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000398 · Cited by 291
Hack, S. P., Zhu, A. X., & Wang, Y. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.598877 · Cited by 286
Qian, J., Wang, C., Wang, B., Yang, J., Wang, Y., Luo, F., Xu, J., Zhao, C., Liu, R., & Chu, Y. (2018) · Journal of Neuroinflammation · doi:10.1186/s12974-018-1330-2 · Cited by 260
Fang, W., Zhou, T., Shi, H., Yao, M., Zhang, D., Qian, H., Zeng, Q., Wang, Y., Jin, F., Chai, C., et al. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-01786-6 · Cited by 256
Hirahara, K., Ghoreschi, K., Yang, X.-P., Takahashi, H., Laurence, A., Vahedi, G., Sciumè, G., Hall, A. O., Dupont, C. D., Francisco, L. M., et al. (2012) · Immunity · doi:10.1016/j.immuni.2012.03.024 · Cited by 254
Rini, B. I., Battle, D., Figlin, R. A., George, D. J., Hammers, H., Hutson, T., Jonasch, E., Joseph, R. W., McDermott, D. F., Motzer, R. J., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0813-8 · Cited by 252
Small molecule immunomodulation: the tumor microenvironment and overcoming immune escape
Osipov, A., Saung, M. T., Zheng, L., & Murphy, A. G. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0667-0 · Cited by 241
The Role Of PD-1/PD-L1 Axis In Treg Development And Function: Implications For Cancer Immunotherapy
Cai, J., Wang, D., Zhang, G., & Guo, X. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s221340 · Cited by 241
The efficacy of PD-1/PD-L1 blockade in cold cancers and future perspectives
Majidpoor, J., & Mortezaee, K. (2021) · Clinical Immunology · doi:10.1016/j.clim.2021.108707 · Cited by 236
Lampert, E. J., Zimmer, A., Padget, M., Cimino-Mathews, A., Nair, J. R., Liu, Y., Swisher, E. M., Hodge, J. W., Nixon, A. B., Nichols, E., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-0056 · Cited by 220
Gao, Y., Yang, J., Cai, Y., Fu, S., Zhang, N., Fu, X., & Li, L. (2018) · International Journal of Cancer · doi:10.1002/ijc.31357 · Cited by 217
Optimized fractionated radiotherapy with anti-PD-L1 and anti-TIGIT: a promising new combination
Grapin, M., Richard, C., Limagne, E., Boidot, R., Morgand, V., Bertaut, A., Derangere, V., Laurent, P.-A., Thibaudin, M., Fumet, J. D., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0634-9 · Cited by 217
Immune checkpoint inhibitors: The linchpins of modern immunotherapy
Wilky, B. A. (2019) · Immunological Reviews · doi:10.1111/imr.12766 · Cited by 206
Study and analysis of antitumor resistance mechanism of PD1/PD‐L1 immune checkpoint blocker
Wang, Z., & Wu, X. (2020) · Cancer Medicine · doi:10.1002/cam4.3410 · Cited by 195
Tumour-Associated Macrophages (TAMs) in Colon Cancer and How to Reeducate Them
Yahaya, M. A. F., Lila, M. A. M., Ismail, S., Zainol, M., & Afizan, N. A. R. N. M. (2019) · Journal of Immunology Research · doi:10.1155/2019/2368249 · Cited by 187
Rebelatto, M. C., Midha, A., Mistry, A., Sabalos, C., Schechter, N., Li, X., Jin, X., Steele, K. E., Robbins, P. B., Blake-Haskins, J. A., et al. (2016) · Diagnostic Pathology · doi:10.1186/s13000-016-0545-8 · Cited by 179
Liu, C., Zheng, S., Wang, Z., Wang, S., Wang, X., Yang, L., Xu, H., Cao, Z., Feng, X., Xue, Q., et al. (2022) · Cancer Communications · doi:10.1002/cac2.12327 · Cited by 175
Self-citationUnderstanding and overcoming the resistance of cancer to PD-1/PD-L1 blockade
Shergold, A. L., Millar, R., & Nibbs, R. J. B. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.104258 · Cited by 174
Interaction of SHP‐2 SH2 domains with PD‐1 ITSM induces PD‐1 dimerization and SHP‐2 activation
Patsoukis, N., Duke-Cohan, J. S., Chaudhri, A., Aksoylar, H.-I., Wang, Q., Council, A., Berg, A., Freeman, G. J., & Boussiotis, V. A. (2020) · Communications Biology · doi:10.1038/s42003-020-0845-0 · Cited by 169
Xue, Y., Gao, S., Gou, J., Yin, T., He, H., Wang, Y., Zhang, Y. X., Tang, X., & Wu, R. (2020) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2021.1825376 · Cited by 168
Yin, Z., Yu, M., Ma, T., Zhang, C., Huang, S., Karimzadeh, M. R., Momtazi‐Borojeni, A. A., & Chen, S. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001698 · Cited by 162
The PD‐1/PD‐L1 (B7‐H1) Pathway in Chronic Infection‐Induced Cytotoxic T Lymphocyte Exhaustion
Hofmeyer, K. A., Jeon, H., & Zang, X. (2011) · BioMed Research International · doi:10.1155/2011/451694 · Cited by 160
The MHC I loading complex: a multitasking machinery in adaptive immunity
Hulpke, S., & Tampé, R. (2013) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2013.06.003 · Cited by 159
Lv, Y., Zhao, Y., Wang, X., Chen, N., Mao, F., Teng, Y., Wang, T., Peng, L., Zhang, J., Cheng, P., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0530-3 · Cited by 154
Primary and acquired resistance to PD-1/PD-L1 blockade in cancer treatment
Wang, Q., & Wu, X. (2017) · International Immunopharmacology · doi:10.1016/j.intimp.2017.03.015 · Cited by 153
Combination therapy with PD-1 or PD-L1 inhibitors for cancer
Hayashi, H., & Nakagawa, K. (2019) · International Journal of Clinical Oncology · doi:10.1007/s10147-019-01548-1 · Cited by 151
IL-27 induces the expression of IDO and PD-L1 in human cancer cells
Carbotti, G., Barisione, G., Airoldi, I., Mezzanzanica, D., Bagnoli, M., Ferrero, S., Petretto, A., Fabbi, M., & Ferrini, S. (2015) · Oncotarget · doi:10.18632/oncotarget.6530 · Cited by 149
Adoptive CD8+ T cell therapy against cancer:Challenges and opportunities
Jiang, X., Jiang, X., Liu, M., Xing, H., Wang, Z., Huang, L., Mellor, A. L., Wang, W., & Wu, S. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.07.017 · Cited by 141
Self-citationYee, D., Shah, K., Coles, M. C., Sharp, T. V., & Lagos, D. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.809053 · Cited by 138
Progress and Challenges in Precise Treatment of Tumors With PD-1/PD-L1 Blockade
Jiang, Y., Zhao, X., Fu, J., & Wang, H. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00339 · Cited by 124
Immune system in cancer radiotherapy: Resistance mechanisms and therapy perspectives
Mortezaee, K., & Najafi, M. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.103180 · Cited by 113
Boyero, L., Sánchez-Gastaldo, A., Alonso, M. D., Noguera-Uclés, J. F., Molina‐Pinelo, S., & Bernabé, R. (2020) · Cancers · doi:10.3390/cancers12123729 · Cited by 112
Weiss, S. A., Djureinovic, D., Jessel, S., Krykbaeva, I., Zhang, L., Jilaveanu, L. B., Ralabate, A. L., Johnson, B. J. B., Levit, N. S., Anderson, G., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0903 · Cited by 111
Zhao, T., Li, Y., Zhang, J., & Zhang, B. (2020) · Oncology Letters · doi:10.3892/ol.2020.11647 · Cited by 108
Chen, D., Barsoumian, H. B., Yang, L., Younes, A. I., Verma, V., Hu, Y., Menon, H., Wasley, M., Masropour, F., Mosaffa, S., et al. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0744 · Cited by 107
Angelis, C. D., Fu, X., Cataldo, M. L., Nardone, A., Pereira, R., Veeraraghavan, J., Nanda, S., Qin, L., Sethunath, V., Wang, T., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-4191 · Cited by 105
Guo, Q., Dai, X., Yin, M., Cheng, H., Qian, H., Wang, H., Zhu, D., & Wang, X. (2022) · Military Medical Research · doi:10.1186/s40779-022-00386-z · Cited by 102
Promising approaches in cancer immunotherapy
Taefehshokr, N., Baradaran, B., Baghbanzadeh, A., & Taefehshokr, S. (2019) · Immunobiology · doi:10.1016/j.imbio.2019.11.010 · Cited by 97
Fleming-de-Moraes, C. D., Rocha, M. R., Tessmann, J. W., de Araújo, W. M., & Morgado‐Díaz, J. A. (2022) · Cancer Biology & Therapy · doi:10.1080/15384047.2022.2108690 · Cited by 97
Myeloma Drug Resistance Induced by Binding of Myeloma B7-H1 (PD-L1) to PD-1
Ishibashi, M., Tamura, H., Sunakawa, M., Kondo, A., Okuyama, N., Hamada, Y., Moriya, K., Choi, I., Tamada, K., & Inokuchi, K. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0296 · Cited by 96
Xiao, W. L., Klement, J. D., Lu, C., Ibrahim, M. L., & Liu, K. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1800129 · Cited by 90
Systemic Therapy of Metastatic Melanoma: On the Road to Cure
Steininger, J., Gellrich, F. F., Schulz, A., Westphal, D., Beissert, S., & Meier, F. E. (2021) · Cancers · doi:10.3390/cancers13061430 · Cited by 84
Wang, Z., Wang, X., Xu, Y., Li, J., Zhang, X., Peng, Z., Hu, Y., Zhao, X., Dong, K., Zhang, B., et al. (2022) · BMC Medicine · doi:10.1186/s12916-022-02327-y · Cited by 84
Zuazo, M., Gato, M., Llorente, N., Ibáñez-Vea, M., Arasanz, H., Kochan, G. T., & Escors, D. (2017) · Annals of Translational Medicine · doi:10.21037/atm.2017.06.11 · Cited by 83
β-Catenin mediates tumor-induced immunosuppression by inhibiting cross-priming of CD8+ T cells
Liang, X., Fu, C., Cui, W., Ober-Blöbaum, J. L., Zahner, S. P., Shrikant, P. A., Clausen, B. E., Flavell, R. A., Mellman, I., & Jiang, A. (2013) · Journal of Leukocyte Biology · doi:10.1189/jlb.0613330 · Cited by 74
Hong, A., Piva, M., Liu, S., Hugo, W., Lomeli, S. H., Zoete, V., Randolph, C. E., Yang, Z., Wang, Y., Lee, J. J., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0873 · Cited by 70
Subudhi, S. K., Siddiqui, B. A., Aparicio, A. M., Yadav, S. S., Basu, S., Chen, H., Jindal, S., Tidwell, R. S. S., Varma, A., Logothetis, C. J., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002919 · Cited by 62
de Liaño, A. G., van Dijk, N., de Velasco, G., Necchi, A., Lavaud, P., Morales‐Barrera, R., Gordoa, T. A., Maroto, P., Ravaud, A., Durán, I., et al. (2019) · European Urology · doi:10.1016/j.eururo.2019.10.004 · Cited by 61
Minnar, C. M., Chariou, P. L., Horn, L. A., Hicks, K. C., Palena, C., Schlom, J., & Gameiro, S. R. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-004561 · Cited by 59
Mittal, L., Srivastava, M., Kumari, A., Tonk, R. K., Awasthi, A., & Asthana, S. (2021) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.0c01080 · Cited by 58
PD-1/PD-L1 enhanced cisplatin resistance in gastric cancer through PI3K/AKT mediated P-gp expression
Wu, L., Cai, S., Deng, Y., Zhang, Z., Zhou, X.-H., Su, Y., & Xu, D. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.107443 · Cited by 56
Wang, X., Ni, S., Chen, Q.-Y., Ma, L., Jiao, Z.-X., Wang, C., & Jia, G. (2016) · Cell Biology International · doi:10.1002/cbin.10716 · Cited by 51
Research progress of PD-1/PD-L1 immunotherapy in gastrointestinal tumors
Sun, J., Zheng, Y., Mamun, M., Li, X., Chen, X., & Gao, Y. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110504 · Cited by 51
EGFR‐ERK pathway regulates CSN6 to contribute to PD‐L1 expression in glioblastoma
Su, L., Guo, W., Lou, L., Nie, S., Zhang, Q. H., Liu, Y., Chang, Y., Zhang, X., Li, Y., & Shen, H. (2020) · Molecular Carcinogenesis · doi:10.1002/mc.23176 · Cited by 50
Benhamouda, N., Sam, I., Epaillard, N., Gey, A., Phan, L., Pham, H., Gruel, N., Saldmann, A., Pineau, J., Hasan, M., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-0905 · Cited by 50
Redox tolerance and metabolic reprogramming in solid tumors
Mortezaee, K. (2020) · Cell Biology International · doi:10.1002/cbin.11506 · Cited by 49
Enhancing PD-L1 Degradation by ITCH during MAPK Inhibitor Therapy Suppresses Acquired Resistance
Yang, Z., Wang, Y., Liu, S., Deng, W., Lomeli, S. H., Moriceau, G., Wohlschlegel, J. A., Piva, M., & Lo, R. S. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-1463 · Cited by 48
Cheng, C., Lin, H., Tsai, K.-J., Chiang, Y., Lim, K., Chen, C. G., Su, Y., Peng, C., Ho, A., Huang, L., et al. (2018) · Molecular Carcinogenesis · doi:10.1002/mc.22881 · Cited by 44
Effect of radiotherapy on T cell and PD-1 / PD-L1 blocking therapy in tumor microenvironment
Chen, C., Liu, Y., & Cui, B. (2021) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2020.1840254 · Cited by 44
Immunotherapy in non-small cell lung cancer: rationale, recent advances and future perspectives
Luo, W., Wang, Z., Zhang, T., Yang, L., Xian, J., Li, Y., & Li, W. (2021) · Precision Clinical Medicine · doi:10.1093/pcmedi/pbab027 · Cited by 42
Koseska, A., & Bastiaens, P. I. H. (2020) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev-cellbio-013020-103810 · Cited by 39
Konstantinopoulos, P. A., Cheng, S., Supko, J. G., Polak, M. M., Wahner-Hendrickson, A. E., Ivy, S. P., Bowes, B., Sawyer, H., Basada, P., Hayes, M., et al. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01664-8 · Cited by 39
PD-1 Blockade in Early-Stage Lung Cancer
Rosner, S., Reuss, J. E., & Forde, P. M. (2018) · Annual Review of Medicine · doi:10.1146/annurev-med-050217-025205 · Cited by 38
Ma, L., Diao, B., Huang, Z., Wang, B., Yu, J., & Meng, X. (2021) · 癌症:英文版 · doi:10.1002/cac2.12229 · Cited by 36
Mechanisms of Resistance to Immune Checkpoint Antibodies
Ramos, R. N., Piaggio, E., & Romano, E. (2017) · Handbook of experimental pharmacology · doi:10.1007/164_2017_11 · Cited by 34
Ivosidenib in IDH1-mutated cholangiocarcinoma: Clinical evaluation and future directions
Lavacchi, D., Caliman, E., Rossi, G., Buttitta, E., Botteri, C., Fancelli, S., Pellegrini, E., Roviello, G., Pillozzi, S., & Antonuzzo, L. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108170 · Cited by 34
Targeting PD-1/PD-L1 axis as new horizon for ovarian cancer therapy
Khatoon, E., Parama, D., Kumar, A., Alqahtani, M. S., Abbas, M. A. E., Girisa, S., Sethi, G., & Kunnumakkara, A. B. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.120827 · Cited by 34
Combination Approaches to Target PD-1 Signaling in Cancer
Moore, E. K., Strazza, M., & Mor, A. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.927265 · Cited by 33
Korentzelos, D. K., Wells, A. H., & Clark, A. M. (2022) · Scientific Reports · doi:10.1038/s41598-022-10724-9 · Cited by 32
Aguado, C., Chara, L. E., Antoñanzas, M., Matilla-González, J. M., Jiménez, U., Hernánz, R., Mielgo-Rubio, X., Trujillo-Reyes, J. C., & Couñago, F. (2022) · World Journal of Clinical Oncology · doi:10.5306/wjco.v13.i5.314 · Cited by 32
Xiong, H.-Y., Ma, T., Wu, B., Lin, Y., & Tu, Z. (2014) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2014.15.14.5767 · Cited by 31
Ovarian Cancer-Associated Ascites Have High Proportions of Cytokine-Responsive CD56bright NK Cells
Tonetti, C. R., de Souza-Araújo, C. N., Yoshida, A., da Silva, R. F., Alves, P. C. M., Mazzola, T. N., Derchain, S., Fernandes, L. G. R., & Guimarães, F. (2021) · Cells · doi:10.3390/cells10071702 · Cited by 29
Yoo, K. J., Johannes, K., Gonzalez, L. E., Patel, A., Shuptrine, C. W., Opheim, Z., Lenz, K. L., Campbell, K., Nguyen, T., Miriyala, J., et al. (2022) · The Journal of Immunology · doi:10.4049/jimmunol.2101175 · Cited by 25
The Immunological Role of CDK4/6 and Potential Mechanism Exploration in Ovarian Cancer
Liu, C., Huang, Y., Cui, Y., Zhou, J., Qin, X., Zhang, L., Li, X., Li, Y., Guo, E., Yang, B., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2021.799171 · Cited by 24
Self-citationPembrolizumab for the treatment of Hodgkin Lymphoma
Hadidi, S. A., & Lee, H. J. (2020) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2020.1830056 · Cited by 23
Clinical benefit of neoadjuvant anti‐PD‐1/PD‐L1 utilization among different tumors
Li, Z., Wu, X., Zhao, Y., Xiao, Y., Zhao, Y., Zhang, T., Li, H., Sha, F., Wang, Y., Deng, L., et al. (2021) · MedComm · doi:10.1002/mco2.61 · Cited by 23
Integrating CDK4/6 inhibitors in the treatment of patients with early breast cancer
Loibl, S., & Furlanetto, J. (2021) · The Breast · doi:10.1016/j.breast.2021.12.008 · Cited by 23
CDK 4/6 inhibitors for the treatment of meningioma
Young, J. S., Kidwell, R. L., Zheng, A., Haddad, A. F., Aghi, M. K., Raleigh, D. R., Schulte, J. D., & Butowski, N. A. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.931371 · Cited by 22
Ahn, A., Rodger, E. J., Motwani, J., Gimenez, G., Stockwell, P. A., Parry, M. F., Hersey, P., Chatterjee, A., & Eccles, M. R. (2021) · Cancers · doi:10.3390/cancers13174250 · Cited by 21
Mussafi, O., Mei, J., Mao, W., & Wan, Y. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.948405 · Cited by 21
Overcoming Immune Resistance With Radiation Therapy in Prostate Cancer
Mulvey, A., Muggeo-Bertin, E., Berthold, D., & Herrera, F. G. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.859785 · Cited by 19
Adusumilli, P. S., Cha, E., Cornfeld, M. J., Davis, T. A., Diab, A. K., Dubensky, T. W., Evans, E. E., Grogan, J. L., Irving, B. A., Leidner, R. S., et al. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0253-2 · Cited by 17
Apostolidis, J. P., Sayyed, A., Darweesh, M., Kaloyannidis, P., & Hashmi, H. A. (2020) · Journal of Immunology Research · doi:10.1155/2020/9350272 · Cited by 17
Mittal, L., Tonk, R. K., Awasthi, A., & Asthana, S. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00176 · Cited by 17
Integrin α2β1 Represents a Prognostic and Predictive Biomarker in Primary Ovarian Cancer
Dötzer, K., Schlüter, F., von Koch, F. E., Brambs, C., Anthuber, S., Frangini, S., Czogalla, B., Burges, A., Werner, J., Mahner, S., et al. (2021) · Biomedicines · doi:10.3390/biomedicines9030289 · Cited by 16
Exosomes-mediated tumor treatment: One body plays multiple roles
Xu, N., Guo, R., Yang, X., Li, N., Yu, J., & Zhang, P. (2021) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2021.08.003 · Cited by 16
Self-citationResistance mechanisms to programmed cell death protein 1 and programmed death ligand 1 inhibitors
Pezeshki, P. S., Sharif, P. M., & Rezaei, N. (2021) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2021.1929919 · Cited by 14
Meijing, Z., Tianhang, L., & Biao, Y. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.913307 · Cited by 14
Palicelli, A., Bonacini, M., Croci, S., Bisagni, A., Zanetti, E., de Biase, D., Sanguedolce, F., Ragazzi, M., Zanelli, M., Chaux, A., et al. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11121312 · Cited by 11
Response to Anti-PD-1 in Microsatellite-Stable Colorectal Cancer: A STAT Need
Nusrat, M. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2901 · Cited by 9
PD-1/L1 inhibitor plus chemotherapy in the treatment of sarcomas
Tian, Z., & Yao, W. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.898255 · Cited by 8
Cited by
Ming, Z., Zhang, Y., Song, L., Chen, M., Lin, L., He, Y., Liu, W., Zhu, Y., Zhang, Y., & Zhang, G. (2024) · Advanced Science · doi:10.1002/advs.202309992 · Cited by 13
Metadata
- Authors
- Pang, K., Shi, Z.-D., Wei, L.-Y., Dong, Y., Ma, Y.-Y., Wang, W., Wang, G.-Y., Cao, M.-Y., Dong, J.-J., Chen, Y.-A., Zhang, P., Hao, L., Xu, H., Pan, D., Chen, Z.-S., & Han, C.-H.
- Venue
- Drug Resistance Updates
- Publisher
- Elsevier BV
- Published
- 2023-01
- Volume
- 66
- Pages
- 100907
- ISSN
- 1368-7646 (ISSN-L)
- OpenAlex
- W4310424284
- Cited by
- 260
- References
- 164
- FWCI
- 17.40
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.